Medicinal Utility of Thiosemicarbazones with Special Reference to Mixed Ligand and Mixed Metal Complexes: A Review

T. Khan; S. Raza; A. J. Lawrence

doi:10.1134/s1070328422600280

journal article Dec 01, 2022

Medicinal Utility of Thiosemicarbazones with Special Reference to Mixed Ligand and Mixed Metal Complexes: A Review

T. Khan S. Raza A. J. Lawrence

Russian Journal of Coordination Chemistry Vol. 48 No. 12 pp. 877-895 · Pleiades Publishing Ltd

View at Publisher Save 10.1134/s1070328422600280

Topics

No keywords indexed for this article. Browse by subject →

References

186

[1]

Kola, I. and Landis, J., Nature Rev. Drug Dis., 2004, vol. 3, p. 711. 10.1038/nrd1470

[2]

Pelosi, G., The Open Crystallography J., 2010, vol. 3, p. 16. 10.2174/1874846501003020016

[3]

Sartorelli, A.C. and Booth, B.A., Cancer Res., 1967, vol. 27, p. 1614.

[4]

Nutting, C.M., van Herpen, C.M.L., and Miah, A.B., Annals Oncol., 2009, vol. 20, no. 7, p. 1275. 10.1093/annonc/mdn775

[5]

Ma, B., Goh, B.C., Tan, E.H., et al., Investigational New Drugs, 2008, vol. 26, no. 2, p. 169. 10.1007/s10637-007-9085-0

[6]

Kasuga, N.C., Sekino, K., Ishikawa, M., et al., J. Inorg. Biochem., 2003, vol. 96, nos. 2−3, p. 298. 10.1016/s0162-0134(03)00156-9

[7]

Brockman, R.W., Thomson, J.R., Bell, M.J., et al., Cancer Res., 1956, vol. 16, p. 167.

[8]

French, F.A. and Blanz, E.J.J., Cancer Res., 1965, vol. 25, no. 9, p. 1454.

[9]

Ferrari, M.B., Bisceglie, F., Pelosi, G., et al., Inorg. Biochem., 2004, vol. 98, p. 301. 10.1016/j.jinorgbio.2003.09.011

[10]

Quiroga, A.G. and Ranninger, C.N., Coord. Chem. Rev., 2004, vol. 248, p. 119. 10.1016/j.cct.2003.11.004

[11]

Dilworth, J.R. and Hueting, R., Inorg. Chim. Acta, 2012, vol. 389, p. 3. 10.1016/j.ica.2012.02.019

[12]

Valdes-Martinez, J., Toscano, R.A., Salcedo, R., et al., Monatsh. Chem., 1990, vol. 121, p. 641. 10.1007/bf00809767

[13]

Beiles, R.H. and Calvin, M., J. Am. Chem. Soc., 1947, vol. 69, no. 8, p. 1886. 10.1021/ja01200a013

[14]

Al-Jeboori., M. and Dawood, A.H., J. Kerbala Univ., 2008, vol. 6, p. 133.

[15]

Chandra, S., Sangeetika, C., and Rathi, A., J. Saudi Chem. Soc., 2001, vol. 5, p. 175.

[16]

Sahin, M., Bal-Demirci, T., Pozan-Soylu, G., et al., Inorg. Chim. Acta, 2009, vol. 362, p. 2407. 10.1016/j.ica.2008.10.036

[17]

John, R.P., Sreekanth, A., Rajakannan, V., et al., Polyhedron, 2004, vol. 23, p. 2549. 10.1016/j.poly.2004.09.004

[18]

Ejidike, I.P. and Ajibade, P.A., Rev. Inorg. Chem., 2015, vol. 35, no. 4, p. 191. 10.1515/revic-2015-0007

[19]

Lobana, T.S., Sharma, R., Bawa, G., et al., Coord. Chem. Rev., 2009, vol. 253, nos. 7−8, p. 977. 10.1016/j.ccr.2008.07.004

[20]

Chikate, R.C. and Padhye, S.B., Spectrochim. Acta, Part A, 2007, vol. 66, nos. 4–5, p. 1091. 10.1016/j.saa.2006.05.017

[21]

Cowley, A.R., Dilworth, J.R., Donnelly, P.S., et al., Dalton Trans., 2003, vol. 4, p. 748. 10.1039/b210540n

[22]

Kovala-Demertzi, D., Yadav, P.N., Wiecek, J., et al., J. Inorg. Biochem., 2006, vol. 100, no. 9, p. 1558. 10.1016/j.jinorgbio.2006.05.006

[23]

Philip, V., Suni, V., Kurup, M., et al., Polyhedron, 2005, vol. 24, no. 10, p. 1133. 10.1016/j.poly.2005.03.064

[24]

An Electrochemical Study of Antineoplastic Gallium, Iron and Ruthenium Complexes with Redox Noninnocent α-N-Heterocyclic Chalcogensemicarbazones

Christian R. Kowol, Erwin Reisner, Ion Chiorescu et al.

Inorganic Chemistry 2008 10.1021/ic8013249

[25]

The Hallmarks of Cancer

Douglas Hanahan, Robert A Weinberg

Cell 2000 10.1016/s0092-8674(00)81683-9

[26]

Hodgson, S., J. Zhejiang Univ. Sci., B., 2008, vol. 9, no. 1, p. 1. 10.1631/jzus.b073001

[27]

Corrie, P.G. and Pippa, G., Medicine, 2008, vol. 36, no. 1, p. 24. 10.1016/j.mpmed.2007.10.012

[28]

Sathisha, M.P., Budagumpi, S., Kulkarni, N.V., et al., Eur. J. Med. Chem., 2010, vol. 45, no. 1, p. 106. 10.1016/j.ejmech.2009.09.031

[29]

Jakupec, M.A., Galanski, M., Arion, V.B., et al., Dalton Trans., 2008, p. 183. 10.1039/b712656p

[30]

Sharma, B. and Kothari, R., Int. J. Pharma Bio. Sci., 2015, vol. 6, no. 1, p. 1154.

[31]

Manikandan, R., Vijayan, P., Anitha, P., et al., Inorg. Chim. Acta, 2014, vol. 421, p. 80. 10.1016/j.ica.2014.05.035

[32]

Palanimuthu, D., Shinde, S.V., Somasundaram, K., et al., J. Med. Chem., 2013, vol. 56, no. 3, p. 722. 10.1021/jm300938r

[33]

Naidu, P.V.S. and Prakash, M.S.K., Int. J. Pharma Med. Bio Sci., 2012, vol. 1, no. 2, p. 55.

[34]

Enyedy, E.A., Nagy, N.V., Zsigo, E., et al., Eur. J. Inorg. Chem., 2010, vol. 11, p. 1717. 10.1002/ejic.200901174

[35]

Shao, J., Zhou, B., Di Bilio, A.J., et al., Mol. Cancer Ther., 2006, vol. 5, no. 3, p. 586. 10.1158/1535-7163.mct-05-0384

[36]

Hall, I.H., Lackey, C.B., Kistler, T.D., et al., Pharmazie, 2000, vol. 55, no. 12, p. 937.

[37]

Ludwig, J.A., Szakacs, G., Martin, S.E., et al., Cancer Res., 2006, vol. 66, no. 9, p. 4808. 10.1158/0008-5472.can-05-3322

[38]

Beraldo, H.O. and Gambino, D., Mini Rev. Med. Chem., 2004, vol. 4, p. 31.

[39]

The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer

Danuta S. Kalinowski, Des R. Richardson

Pharmacological Reviews 2005 10.1124/pr.57.4.2

[40]

Nitiss, J.L. Nature Rev. Cancer, 2009, vol. 9, p. 327. 10.1038/nrc2608

[41]

Chen, J., Huang, Y.W., Liu, G., et al., Toxicol. Appl. Pharmacol., 2004, vol. 197, p. 40. 10.1016/j.taap.2004.02.004

[42]

Zeglis, B.M., Divilov, V., and Lewis, J.S., J. Med. Chem., 2011, vol. 54, no. 7, p. 2391. 10.1021/jm101532u

[43]

McGill, B., Snyder, H.M., Probasco, M., et al., Abstracts of Papers, 247th ACS National Meeting and Exposition, Dallas, USA, 2014.

[44]

Gómez-Saiz, P., Gil-García, R., Maestro, M.A., et al., J. Inorg. Biochem., 2008, vol. 102, no. 10, p. 1910. 10.1016/j.jinorgbio.2008.06.015

[45]

Chen, J.S.K., Agarwal, N., and Mehta, K., Breast Cancer Res. Treatment, 2002, vol. 71, no. 3, p. 237. 10.1023/a:1014461832403

[46]

Padhye, S., Afrasiabi, Z., Sinn, E., et al., Inorg. Chem., 2005, vol. 44, no. 5, p. 1154. 10.1021/ic048214v

[47]

Szakа́cs G., Annereau, J.-P. Lababidi, S., et al., Cancer Cell, 2004, vol. 6, no. 2, p. 129. 10.1016/j.ccr.2004.06.026

[48]

Ludwig, J.A., Gergely, S., Martin, S.E., et al., Cancer Res., 2006, vol. 66, no. 9, p. 4808. 10.1158/0008-5472.can-05-3322

[49]

Bai, J., Wang, R-H., Qiao, Y., et al., Drug Des. Dev. Ther., 2017, vol. 11, p. 2227. 10.2147/dddt.s138371

[50]

Balabanova, Y., Gilsdorf, A., Buda, S., et al., PLoS One, 2011, vol. 6, p. e25691. 10.1371/journal.pone.0025691

Showing 50 of 186 references

Cited By

40

Recent Advances in the Multicomponent Synthesis of Heterocycles using Thiosemicarbazide

Ramin Javahershenas, Mosstafa Kazemi · 2024

ChemistrySelect

Metrics

40

Citations

186

References

Details

Published: Dec 01, 2022
Vol/Issue: 48(12)
Pages: 877-895
License: View

Authors

Cite This Article

T. Khan, S. Raza, A. J. Lawrence (2022). Medicinal Utility of Thiosemicarbazones with Special Reference to Mixed Ligand and Mixed Metal Complexes: A Review. Russian Journal of Coordination Chemistry, 48(12), 877-895. https://doi.org/10.1134/s1070328422600280

Medicinal Utility of Thiosemicarbazones with Special Reference to Mixed Ligand and Mixed Metal Complexes: A Review

You May Also Like